Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 6:jiac118. doi: 10.1093/infdis/jiac118

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Vaccine effectiveness of mRNA vaccination against coronavirus disease 2019 (COVID-19) hospitalization by immune status group. Separate estimates were calculated for 2 doses of an mRNA vaccine and 3 doses of an mRNA vaccine. *Models were adjusted for calendar time of admission (in biweekly intervals), US Health and Human Services region, age group (18–49, 50–64, or ≥65 years), sex, and race and Hispanic ethnicity. ^†Post hoc P value comparisons of vaccine effectiveness for 2 doses vs 3 doses of an mRNA vaccine were obtained using the pwcompare function in Stata ^§Defined as receiving supplemental oxygen support or having a documented oxygen saturation <92% within 24 hours of admission. This analysis was restricted to cases who met criteria for hypoxemia within 24 hours of admission and all control patients (ie, including those with or without hypoxemia).